Physician profile
Thomas A Grady
NPI 1962400754
$52,244.00
in general payments reported to CMS, 2019-2025
34 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $625 · 2021: $7,622 · 2022: $13K · 2023: $8,472 · 2024: $4,674 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $4,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,200.00 |
| Food and Beverage | $4,054.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46,329.75 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,102.12 | 2019-2025 | |
| Amgen INC. | $1,025.79 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $516.27 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $459.65 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.92 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $249.76 | 2022-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $201.02 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $193.48 | 2020-2025 | Farxiga, Brilinta, Lokelma |
| Abbott Laboratories | $182.35 | 2019-2025 | Amplatzer Amulet, Navitor |
| Lexicon Pharmaceuticals, INC. | $151.32 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $133.94 | 2024-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $121.98 | 2019-2025 | Watchman |
| Amarin Pharma, INC. | $112.29 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.26 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $111.34 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $101.35 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.52 | 2019-2025 | Lifevest |
| Irhythm Technologies, INC. | $79.72 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Bridgebio Pharma, INC. | $72.95 | 2025 | Attruby |
| Vifor Pharma, INC. | $56.76 | 2019-2021 | |
| Medtronic, INC. | $53.09 | 2021-2023 | Micra |
| Baxter Healthcare | $51.17 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Scpharmaceuticals INC. | $50.75 | 2024-2025 | |
| Medtronic Vascular, INC. | $39.97 | 2020 | |
| Arbor Pharmaceuticals, INC. | $38.13 | 2019-2021 | |
| Novo Nordisk INC | $34.17 | 2024-2025 | Wegovy |
| Esperion Therapeutics, INC. | $32.70 | 2020-2024 | Nexletol |
| Genzyme Corporation | $24.27 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $21.17 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $20.77 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $19.08 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.70 | 2019 | |
| Vapotherm INC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.